Nervous System Involvement in Coronavirus Disease 2019: Results from a Retrospective Consecutive Neuroimaging Cohort.


Journal

Radiology
ISSN: 1527-1315
Titre abrégé: Radiology
Pays: United States
ID NLM: 0401260

Informations de publication

Date de publication:
12 2020
Historique:
pubmed: 31 7 2020
medline: 1 12 2020
entrez: 31 7 2020
Statut: ppublish

Résumé

Background Neurologic complications in coronavirus disease 2019 (COVID-19) have been described, but the understanding of their pathophysiologic causes and neuroanatomical correlates remains limited. Purpose To report on the frequency and type of neuroradiological findings in COVID-19. Materials and Methods In this retrospective study, all consecutive adult hospitalized patients with polymerase chain reaction positivity for severe acute respiratory syndrome coronavirus 2 and who underwent neuroimaging at Karolinska University Hospital between March 2 and May 24, 2020, were included. All examinations were systematically re-evaluated by 12 readers. Summary descriptive statistics were calculated. Results A total of 185 patients with COVID-19 (62 years ± 14 [standard deviation]; 138 men) underwent neuroimaging. In total, 222 brain CT, 47 brain MRI, and seven spinal MRI examinations were performed. Intra-axial susceptibility abnormalities were the most common finding (29 of 39; 74%, 95% CI: 58, 87) in patients who underwent brain MRI, often with an ovoid shape suggestive of microvascular pathology and with a predilection for the corpus callosum (23 of 39; 59%; 95% CI: 42, 74) and juxtacortical areas (14 of 39; 36%; 95% CI: 21, 53). Ischemic and macrohemorrhagic manifestations were also observed, but vascular imaging did not demonstrate overt abnormalities. Dynamic susceptibility contrast perfusion MRI in 19 patients did not reveal consistent asymmetries between hemispheres or regions. Many patients (18 of 41; 44%; 95% CI: 28, 60) had leukoencephalopathy and one patient had a cytotoxic lesion of the corpus callosum. Other findings included olfactory bulb signal abnormalities (seven of 37; 19%), prominent optic nerve subarachnoid spaces (20 of 36; 56%), and enhancement of the parenchyma (three of 20; 15%), leptomeninges (three of 20; 15%), cranial nerves (two of 20; 10%), and spinal nerves (two of four; 50%). At MRI follow-up, regression of leukoencephalopathy and progressive leptomeningeal enhancement was observed in one patient each, respectively, which is suggestive of dynamic processes. Conclusion Patients with coronavirus disease 2019 had a wide spectrum of vascular and inflammatory involvement of both the central and peripheral nervous system. © RSNA, 2020

Identifiants

pubmed: 32729812
doi: 10.1148/radiol.2020202791
pmc: PMC7393954
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

E324-E334

Références

J Neuroimaging. 2020 Sep;30(5):593-597
pubmed: 32639679
J Stroke Cerebrovasc Dis. 2016 Nov;25(11):e214-e215
pubmed: 27693106
J Neurol Sci. 2020 Jun 15;413:116832
pubmed: 32299017
Ann Intern Med. 2020 Aug 18;173(4):268-277
pubmed: 32374815
N Engl J Med. 2020 Jun 4;382(23):2268-2270
pubmed: 32294339
Neurocrit Care. 2011 Aug;15(1):156-60
pubmed: 21465323
N Engl J Med. 2020 Sep 3;383(10):989-992
pubmed: 32530583
JAMA Neurol. 2020 Aug 1;77(8):1018-1027
pubmed: 32469387
AJNR Am J Neuroradiol. 2009 Jun;30(6):e85-6
pubmed: 19321625
N Engl J Med. 2020 May 14;382(20):e60
pubmed: 32343504
JAMA Neurol. 2020 Jun 1;77(6):683-690
pubmed: 32275288
Stroke. 2017 Apr;48(4):1085-1087
pubmed: 28235962
Neurology. 2015 Jul 7;85(1):18-28
pubmed: 25888557
J Neurol Sci. 2020 Jul 15;414:116884
pubmed: 32464367
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Radiology. 2020 Sep;296(3):E184-E185
pubmed: 32407258
JAMA Neurol. 2020 Aug 1;77(8):1028-1029
pubmed: 32469400
AJNR Am J Neuroradiol. 2019 Mar;40(3):464-469
pubmed: 30679208
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
J Radiol Case Rep. 2011;5(8):1-7
pubmed: 22470806
Radiology. 2020 Oct;297(1):E232-E235
pubmed: 32384020
Neurology. 2020 Oct 6;95(14):e2016-e2027
pubmed: 32546654
Radiology. 2020 Oct;297(1):E223-E227
pubmed: 32437314
AJNR Am J Neuroradiol. 2018 Mar;39(3):532-537
pubmed: 29269404
Radiology. 2020 Nov;297(2):E270-E273
pubmed: 32437313
Radiology. 2020 Nov;297(2):E242-E251
pubmed: 32544034
Neurology. 2009 Nov 24;73(21):1759-66
pubmed: 19933977
Int J Infect Dis. 2020 May;94:55-58
pubmed: 32251791
N Engl J Med. 2020 Jul 23;383(4):400-401
pubmed: 32383831
N Engl J Med. 2020 Jun 25;382(26):e110
pubmed: 32453515
Nat Rev Neurol. 2013 Jun;9(6):307-16
pubmed: 23628737
J Neuroimaging. 2017 Jan;27(1):43-49
pubmed: 27539492

Auteurs

Stefanos Klironomos (S)

From the Department of Neuroradiology (S.K., A.T., A.K., C.Ö., E.K., H.A., Å.A., H.M., R.O., M. Hasselberg, M. Haghgou, M.P., J.F., J.L., A.F.D., T.G.), Department of Neurology (A.A.), and Department of Medical Radiation Physics and Nuclear Medicine (S.P.), Karolinska University Hospital, 141 86, Stockholm, Sweden; Department of Clinical Neuroscience (S.K., A.K., C.Ö., H.A., Å.A., R.O., J.A.S., M. Hasselberg., J.F., J.L., A.F.D., T.G.) and Department of Department of Clinical Science, Intervention and Technology (A.T., S.P.), Karolinska Institutet, Stockholm, Sweden.

Antonios Tzortzakakis (A)

From the Department of Neuroradiology (S.K., A.T., A.K., C.Ö., E.K., H.A., Å.A., H.M., R.O., M. Hasselberg, M. Haghgou, M.P., J.F., J.L., A.F.D., T.G.), Department of Neurology (A.A.), and Department of Medical Radiation Physics and Nuclear Medicine (S.P.), Karolinska University Hospital, 141 86, Stockholm, Sweden; Department of Clinical Neuroscience (S.K., A.K., C.Ö., H.A., Å.A., R.O., J.A.S., M. Hasselberg., J.F., J.L., A.F.D., T.G.) and Department of Department of Clinical Science, Intervention and Technology (A.T., S.P.), Karolinska Institutet, Stockholm, Sweden.

Annika Kits (A)

From the Department of Neuroradiology (S.K., A.T., A.K., C.Ö., E.K., H.A., Å.A., H.M., R.O., M. Hasselberg, M. Haghgou, M.P., J.F., J.L., A.F.D., T.G.), Department of Neurology (A.A.), and Department of Medical Radiation Physics and Nuclear Medicine (S.P.), Karolinska University Hospital, 141 86, Stockholm, Sweden; Department of Clinical Neuroscience (S.K., A.K., C.Ö., H.A., Å.A., R.O., J.A.S., M. Hasselberg., J.F., J.L., A.F.D., T.G.) and Department of Department of Clinical Science, Intervention and Technology (A.T., S.P.), Karolinska Institutet, Stockholm, Sweden.

Claes Öhberg (C)

From the Department of Neuroradiology (S.K., A.T., A.K., C.Ö., E.K., H.A., Å.A., H.M., R.O., M. Hasselberg, M. Haghgou, M.P., J.F., J.L., A.F.D., T.G.), Department of Neurology (A.A.), and Department of Medical Radiation Physics and Nuclear Medicine (S.P.), Karolinska University Hospital, 141 86, Stockholm, Sweden; Department of Clinical Neuroscience (S.K., A.K., C.Ö., H.A., Å.A., R.O., J.A.S., M. Hasselberg., J.F., J.L., A.F.D., T.G.) and Department of Department of Clinical Science, Intervention and Technology (A.T., S.P.), Karolinska Institutet, Stockholm, Sweden.

Evangelia Kollia (E)

From the Department of Neuroradiology (S.K., A.T., A.K., C.Ö., E.K., H.A., Å.A., H.M., R.O., M. Hasselberg, M. Haghgou, M.P., J.F., J.L., A.F.D., T.G.), Department of Neurology (A.A.), and Department of Medical Radiation Physics and Nuclear Medicine (S.P.), Karolinska University Hospital, 141 86, Stockholm, Sweden; Department of Clinical Neuroscience (S.K., A.K., C.Ö., H.A., Å.A., R.O., J.A.S., M. Hasselberg., J.F., J.L., A.F.D., T.G.) and Department of Department of Clinical Science, Intervention and Technology (A.T., S.P.), Karolinska Institutet, Stockholm, Sweden.

Amir Ahoromazdae (A)

From the Department of Neuroradiology (S.K., A.T., A.K., C.Ö., E.K., H.A., Å.A., H.M., R.O., M. Hasselberg, M. Haghgou, M.P., J.F., J.L., A.F.D., T.G.), Department of Neurology (A.A.), and Department of Medical Radiation Physics and Nuclear Medicine (S.P.), Karolinska University Hospital, 141 86, Stockholm, Sweden; Department of Clinical Neuroscience (S.K., A.K., C.Ö., H.A., Å.A., R.O., J.A.S., M. Hasselberg., J.F., J.L., A.F.D., T.G.) and Department of Department of Clinical Science, Intervention and Technology (A.T., S.P.), Karolinska Institutet, Stockholm, Sweden.

Håkan Almqvist (H)

From the Department of Neuroradiology (S.K., A.T., A.K., C.Ö., E.K., H.A., Å.A., H.M., R.O., M. Hasselberg, M. Haghgou, M.P., J.F., J.L., A.F.D., T.G.), Department of Neurology (A.A.), and Department of Medical Radiation Physics and Nuclear Medicine (S.P.), Karolinska University Hospital, 141 86, Stockholm, Sweden; Department of Clinical Neuroscience (S.K., A.K., C.Ö., H.A., Å.A., R.O., J.A.S., M. Hasselberg., J.F., J.L., A.F.D., T.G.) and Department of Department of Clinical Science, Intervention and Technology (A.T., S.P.), Karolinska Institutet, Stockholm, Sweden.

Åsa Aspelin (Å)

From the Department of Neuroradiology (S.K., A.T., A.K., C.Ö., E.K., H.A., Å.A., H.M., R.O., M. Hasselberg, M. Haghgou, M.P., J.F., J.L., A.F.D., T.G.), Department of Neurology (A.A.), and Department of Medical Radiation Physics and Nuclear Medicine (S.P.), Karolinska University Hospital, 141 86, Stockholm, Sweden; Department of Clinical Neuroscience (S.K., A.K., C.Ö., H.A., Å.A., R.O., J.A.S., M. Hasselberg., J.F., J.L., A.F.D., T.G.) and Department of Department of Clinical Science, Intervention and Technology (A.T., S.P.), Karolinska Institutet, Stockholm, Sweden.

Heather Martin (H)

From the Department of Neuroradiology (S.K., A.T., A.K., C.Ö., E.K., H.A., Å.A., H.M., R.O., M. Hasselberg, M. Haghgou, M.P., J.F., J.L., A.F.D., T.G.), Department of Neurology (A.A.), and Department of Medical Radiation Physics and Nuclear Medicine (S.P.), Karolinska University Hospital, 141 86, Stockholm, Sweden; Department of Clinical Neuroscience (S.K., A.K., C.Ö., H.A., Å.A., R.O., J.A.S., M. Hasselberg., J.F., J.L., A.F.D., T.G.) and Department of Department of Clinical Science, Intervention and Technology (A.T., S.P.), Karolinska Institutet, Stockholm, Sweden.

Russell Ouellette (R)

From the Department of Neuroradiology (S.K., A.T., A.K., C.Ö., E.K., H.A., Å.A., H.M., R.O., M. Hasselberg, M. Haghgou, M.P., J.F., J.L., A.F.D., T.G.), Department of Neurology (A.A.), and Department of Medical Radiation Physics and Nuclear Medicine (S.P.), Karolinska University Hospital, 141 86, Stockholm, Sweden; Department of Clinical Neuroscience (S.K., A.K., C.Ö., H.A., Å.A., R.O., J.A.S., M. Hasselberg., J.F., J.L., A.F.D., T.G.) and Department of Department of Clinical Science, Intervention and Technology (A.T., S.P.), Karolinska Institutet, Stockholm, Sweden.

Jonathan Al-Saadi (J)

From the Department of Neuroradiology (S.K., A.T., A.K., C.Ö., E.K., H.A., Å.A., H.M., R.O., M. Hasselberg, M. Haghgou, M.P., J.F., J.L., A.F.D., T.G.), Department of Neurology (A.A.), and Department of Medical Radiation Physics and Nuclear Medicine (S.P.), Karolinska University Hospital, 141 86, Stockholm, Sweden; Department of Clinical Neuroscience (S.K., A.K., C.Ö., H.A., Å.A., R.O., J.A.S., M. Hasselberg., J.F., J.L., A.F.D., T.G.) and Department of Department of Clinical Science, Intervention and Technology (A.T., S.P.), Karolinska Institutet, Stockholm, Sweden.

Mikael Hasselberg (M)

From the Department of Neuroradiology (S.K., A.T., A.K., C.Ö., E.K., H.A., Å.A., H.M., R.O., M. Hasselberg, M. Haghgou, M.P., J.F., J.L., A.F.D., T.G.), Department of Neurology (A.A.), and Department of Medical Radiation Physics and Nuclear Medicine (S.P.), Karolinska University Hospital, 141 86, Stockholm, Sweden; Department of Clinical Neuroscience (S.K., A.K., C.Ö., H.A., Å.A., R.O., J.A.S., M. Hasselberg., J.F., J.L., A.F.D., T.G.) and Department of Department of Clinical Science, Intervention and Technology (A.T., S.P.), Karolinska Institutet, Stockholm, Sweden.

Mansour Haghgou (M)

From the Department of Neuroradiology (S.K., A.T., A.K., C.Ö., E.K., H.A., Å.A., H.M., R.O., M. Hasselberg, M. Haghgou, M.P., J.F., J.L., A.F.D., T.G.), Department of Neurology (A.A.), and Department of Medical Radiation Physics and Nuclear Medicine (S.P.), Karolinska University Hospital, 141 86, Stockholm, Sweden; Department of Clinical Neuroscience (S.K., A.K., C.Ö., H.A., Å.A., R.O., J.A.S., M. Hasselberg., J.F., J.L., A.F.D., T.G.) and Department of Department of Clinical Science, Intervention and Technology (A.T., S.P.), Karolinska Institutet, Stockholm, Sweden.

Mitra Pedersen (M)

From the Department of Neuroradiology (S.K., A.T., A.K., C.Ö., E.K., H.A., Å.A., H.M., R.O., M. Hasselberg, M. Haghgou, M.P., J.F., J.L., A.F.D., T.G.), Department of Neurology (A.A.), and Department of Medical Radiation Physics and Nuclear Medicine (S.P.), Karolinska University Hospital, 141 86, Stockholm, Sweden; Department of Clinical Neuroscience (S.K., A.K., C.Ö., H.A., Å.A., R.O., J.A.S., M. Hasselberg., J.F., J.L., A.F.D., T.G.) and Department of Department of Clinical Science, Intervention and Technology (A.T., S.P.), Karolinska Institutet, Stockholm, Sweden.

Sven Petersson (S)

From the Department of Neuroradiology (S.K., A.T., A.K., C.Ö., E.K., H.A., Å.A., H.M., R.O., M. Hasselberg, M. Haghgou, M.P., J.F., J.L., A.F.D., T.G.), Department of Neurology (A.A.), and Department of Medical Radiation Physics and Nuclear Medicine (S.P.), Karolinska University Hospital, 141 86, Stockholm, Sweden; Department of Clinical Neuroscience (S.K., A.K., C.Ö., H.A., Å.A., R.O., J.A.S., M. Hasselberg., J.F., J.L., A.F.D., T.G.) and Department of Department of Clinical Science, Intervention and Technology (A.T., S.P.), Karolinska Institutet, Stockholm, Sweden.

Johannes Finnsson (J)

From the Department of Neuroradiology (S.K., A.T., A.K., C.Ö., E.K., H.A., Å.A., H.M., R.O., M. Hasselberg, M. Haghgou, M.P., J.F., J.L., A.F.D., T.G.), Department of Neurology (A.A.), and Department of Medical Radiation Physics and Nuclear Medicine (S.P.), Karolinska University Hospital, 141 86, Stockholm, Sweden; Department of Clinical Neuroscience (S.K., A.K., C.Ö., H.A., Å.A., R.O., J.A.S., M. Hasselberg., J.F., J.L., A.F.D., T.G.) and Department of Department of Clinical Science, Intervention and Technology (A.T., S.P.), Karolinska Institutet, Stockholm, Sweden.

Johan Lundberg (J)

From the Department of Neuroradiology (S.K., A.T., A.K., C.Ö., E.K., H.A., Å.A., H.M., R.O., M. Hasselberg, M. Haghgou, M.P., J.F., J.L., A.F.D., T.G.), Department of Neurology (A.A.), and Department of Medical Radiation Physics and Nuclear Medicine (S.P.), Karolinska University Hospital, 141 86, Stockholm, Sweden; Department of Clinical Neuroscience (S.K., A.K., C.Ö., H.A., Å.A., R.O., J.A.S., M. Hasselberg., J.F., J.L., A.F.D., T.G.) and Department of Department of Clinical Science, Intervention and Technology (A.T., S.P.), Karolinska Institutet, Stockholm, Sweden.

Anna Falk Delgado (A)

From the Department of Neuroradiology (S.K., A.T., A.K., C.Ö., E.K., H.A., Å.A., H.M., R.O., M. Hasselberg, M. Haghgou, M.P., J.F., J.L., A.F.D., T.G.), Department of Neurology (A.A.), and Department of Medical Radiation Physics and Nuclear Medicine (S.P.), Karolinska University Hospital, 141 86, Stockholm, Sweden; Department of Clinical Neuroscience (S.K., A.K., C.Ö., H.A., Å.A., R.O., J.A.S., M. Hasselberg., J.F., J.L., A.F.D., T.G.) and Department of Department of Clinical Science, Intervention and Technology (A.T., S.P.), Karolinska Institutet, Stockholm, Sweden.

Tobias Granberg (T)

From the Department of Neuroradiology (S.K., A.T., A.K., C.Ö., E.K., H.A., Å.A., H.M., R.O., M. Hasselberg, M. Haghgou, M.P., J.F., J.L., A.F.D., T.G.), Department of Neurology (A.A.), and Department of Medical Radiation Physics and Nuclear Medicine (S.P.), Karolinska University Hospital, 141 86, Stockholm, Sweden; Department of Clinical Neuroscience (S.K., A.K., C.Ö., H.A., Å.A., R.O., J.A.S., M. Hasselberg., J.F., J.L., A.F.D., T.G.) and Department of Department of Clinical Science, Intervention and Technology (A.T., S.P.), Karolinska Institutet, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH